252 Clopidogrel increases bleeding complications in patients undergoing heart rhythm device procedures  by Boulé, Stéphane et al.
© Elsevier Masson SAS. All rights reserved.
 
Archives of Cardiovascular Diseases Supplements (2012) 4, 67-81 79
grams of sufentanyl just before epicardial access and that was repeated up to
4 times (20 μg) in case of persistent pain and absence of respiratory depres-
sion. Blood pressure and O2 saturation were continuously monitored.
Results: 74 epicardial VT ablations have been performed in 65 patients (58 M,
58±13yo), 58 (89%) had a structural heart disease with a mean LVEF of 40±15%.
69 were performed under conscious sedation using the above protocol. 5 proce-
dures were performed under GA: 4 because patients had to be sedated for
arrhythmic storm before ablation and 1because of respiratory contraindications.
Mean midazolam and sufentanyl dosages were 4±1,5 mg and 10±5 μg respec-
tively. RF ablation was performed in 57 procedures with mean epicardial RF dura-
tion of 9±11 min for a total procedure time of 243 ±90 min. Because of pericardial
bleeding 2 patients were transferred to the operating room and one patient had
developed metabolic acidosis but no patient had respiratory failure during the pro-
cedure.
Conclusion: Epicardial VT ablation can be performed safely under con-
scious sedation using powerful painkiller such as sufentanyl.
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Acute pericardial effusion following atrial fibrillation ablation: cha-
racteristics and relationship with arrhythmia recurrences
Frédéric Sebag [Orateur] , Nicolas Lellouche, Nathalie Elbaz, Emmanuel
Teiger, Jean Luc Dubois Randé, Pascal Lim
AP-HP, CHU Henri Mondor, Cardiologie, Créteil, France
Background: Pericardial effusion can occur during or after atrial fibrilla-
tion ablation and may induce atrial arrhythmia.
Aims: We aimed to characterize the impact of pericardial effusion on
arrhythmia recurrences following atrial fibrillation ablation.
Methods: We studied prospectively patients referred for a first atrial fibrilla-
tion ablation. We performed transthoracic echocardiography before and 24 hours
after the procedure. If pericardial effusion was present, transthoracic echocardio-
graphy was repeated at one month to evaluate pericardial effusion evolution. Early
arrhythmia recurrences were defined as any arrhythmia documented within
1 month following the procedure. Eighty-one patients were included in our study.
Results: Pericardial effusion was diagnosed in 22% of cases and was present
in 35% of patients with persistent atrial fibrillation vs. 10% for paroxysmal atrial
fibrillation (p=0.008). Pericardial effusions were mild (6±3 mm), asymptomatic
(89%) and none of them required pericardiocentesis.
Early and late arrhythmia recurrences were present in 31% and 36%
respectively in our population. The incidence of pericardial effusion was sig-
nificantly higher in patients with early arrhythmia recurrences compared to
patients without early arrhythmia recurrences (48% vs. 11%, p=0.0004). On
multivariate analysis pericardial effusion and duration in atrial fibrillation
were the two independent predictors of early arrhythmia recurrences.
Pericardial effusion incidence was similar in patients with and without late
arrhythmia recurrences. At one month none of our patients had PE on TTE.
Conclusion: Pericardial effusion following atrial fibrillation ablation is fre-
quent, particularly following persistent atrial fibrillation ablation. This effu-
sion is mild, mainly asymptomatic and independently associated with early
arrhythmia recurrences.
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Aims: We analysed outcomes of 163 patients (pts) with ICD using remote
monitoring follow-up (RFU)
Methods: 163 pts were implanted with an ICD with a Remote Patient
Management (RPM) system. 82 patients (51%) were implanted with biventric-
ular ICDs (CRT-D), 63 (39%) with dual chamber ICDs (D-ICD), and 15 (9%)
with single chamber ICDs (S-ICD). 31 CRT-D pts had also weight and blood
pressure monitoring. RFU was performed every 3 months.
Results: Mean FU with RPM system was 15±10 months. 379 episodes of sus-
tained atrial arrhythmias occured in 13 pts. 287 episodes of ventricular arrhyth-
mias required therapies: 265 (90.6%) were approprialely treated by Anti-
Tachycardia Pacing (ATP), 22 with ICD discharge,only 3 inappropriate shocks. In
the last 7 months of FU, 25 patients were examined at hospital after non-vital
alerts: oral anticoagulation(4 pts) and amiodarone(2 pts) were started, diuretics
dosage increased (5 pts),device reprogrammed in 14 patients. During FU,
5 patients had VT recurrences requiring VT ablation (2 pts),1 pt required a short
heart failure hospitalisation. Pts with S-ICD had less clinical FU in hospital. D-
ICD pts had a higher rate of RFU. In 13 CRT-D pts, alarms indicated biventricular
pacing <85%:we reprogrammed the device (2 pts), changed medical therapeutics
(5 pts), performed AV junction(5 pts) and cavo-tricuspid ablation (1 pt).
Conclusion: RPM is an effective tool for the FU of ICD pts. D-ICDs and
CRT-ICDs had more RPM alerts, and could early detect atrial arrythmias
comparing to S-ICD. RPM helps both physicians and pts for HF management
and for reducing inappropriate ICD shocks.
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Paroxysmal supraventricular tachycardia (SVT) requires a treatment in
patients with recurrent SVT’s. Some of them refuse the radical treatment of
SVT. The purpose of the study was to know the number of patients who
accept SVT ablation, the reasons and the delay between initial electrophysio-
logical study (EPS) and the time of ablation.
Methods: 1268 patients with a normal ECG in sinus rhythm were consec-
utively recruited for SVT’s, confirmed by EPS. Patients with anterograde con-
duction through an accessory pathway (AP) were excluded. Ablation
indications and the time between EPS and ablation were studied.
Results: 652 patients were directly seen for EPS and ablation, because SVT’s
were documented and recurrent (group I). SVT was induced at EPS in
481 patients, but ablation was not performed (group II). Ablation was performed
in a second time after EPS in 135 patients (group III). The mean time between
EPS and ablation was 4±5 years. Group I differs from group II and III by an older
age (53±18 vs 47±19 and 43±18.5 years, p<0.0000), the female gender more fre-
quent than in group II (64.5% vs 55%, p<0.001), but similar in group III (61%).
Syncope associated with SVT was less frequent in group I (7.5%) than in group II
(18/5%) and III (19%) (p<0.0000). The rate in tachycardia was slower in group I
(177±34 bpm) than in group II (189±38) (p<0.0005) and III (193±33) (p<0.0001).
The electrophysiological mechanism was similar in 3 groups. Reentry in a con-
cealed AP was noted in 17.5% of group I patients, 21% of group II patients and
19% of group II patients. Typical and atypical atrioventricular nodal reentrant
tachycardias represent the other causes.
Conclusions: Among patients with proved SVT at EPS, ablation of the
substrate will never be achieved in 38% of patients and will be made at least
4 years after the evaluation in 11% of patients. Only age and gender influence
the decision. Symptoms, rate and mechanism of SVT do not change the indi-
cations of ablation.
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Purpose: Increasing numbers of patients requiring arrhythmia device
implantation are treated with clopidogrel. This study aimed to assess the risk
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of bleeding complications in patients receiving clopidogrel at the time of car-
diac device surgery.
Methods: Between July 2004 and July 2010, 101 consecutive patients
underwent cardiac device surgery (pacemaker or implantable cardioverter-
defibrillator implantation, generator replacement) under clopidogrel therapy in
our institution. Controls were 1:1 matched on age, sex, device, type of proce-
dure, number of leads implanted, and venous approach (cephalic or subcla-
vian). A significant bleeding complication was defined as pocket hematoma
requiring surgical evacuation or prolonged hospitalization, hemothorax, peri-
cardial effusion or tamponade.
Results: Bleeding complications occurred more frequently in patients
receiving clopidogrel at the time of device procedure: 11.9% vs. 4.0%
(p=0,037; OR 3.27 (1.02-10.5)). Bleeding complications were noted in
12 patients (11.9%) receiving clopidogrel, including 10 pocket haematomas,
2 patients with pericardial effusion and one patient with hemothorax. Four
controls (4.0%) had bleeding complications (3 pocket haematomas and one
pericardial effusion). The single factor associated with increased bleeding
complications in patients receiving clopidogrel was subclavian puncture
(p=0.008). In the entire cohort (n=202), multivariate analysis identified sub-
clavian puncture as the single independent predictor of bleeding complications
(p=0.02; OR 3.75 (1.23-11.4)), whereas a non-significant trend was observed
for clopidogrel treatment (p=0,08; OR 3.0 (0.87-10.3)).
Conclusion: Clopidogrel treatment at the time of heart rhythm device pro-
cedures is associated with a 3-fold increased risk of significant bleeding com-
plications. Subclavian puncture strongly increases hemorrhagic complications
in this setting, so as a cephalic cut-down first-line approach appears safer in
these patients.
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Paroxysmal supraventricular tachycardia is considered benign because it
occurs in subjects with healthy heart. When SVT occurs in patients (pts) with
heart disease (HD), the prognosis is unknown. The purpose of the study was
to report the prognosis of SVT occurring in pts with HD.
Methods: 1269 pts, aged from 6 to 93 years (mean 50±19) with a normal
ECG in sinus rhythm, without anterograde conduction through an accessory
pathway (AP) were recruited for SVT’s. Clinical history, echocardiographic
and electrophysiological data were collected. Pts were followed from 3
months to 20 years (mean 3.5±4).
Results: SVT occurred in 133 pts with HD (10%), ischemic HD (59), val-
vular HD (21), congenital HD (5), dilated cardiomyopathy (25), various HD
(23). Their mean age was 62±15 years. Remaining 1136 pts, mean age 48±19
(p<0.0000) had no apparent HD. SVT ablation was performed in 788 pts, 72
with HD (54%), 712 without HD (64%)(NS 0.055). SVT mechanism was sim-
ilar, AV reentrant tachycardia (AVRT) through concealed AP 21% in pts with
HD, 18.5% in pts without HD (NS), atypical or typical AV node RT in
remaining pts. During follow-up, 19 of 133 pts with HD (14%), 56±14.5 years
old, died from cardiovascular (CV) death (sudden death 9, heart failure-related
death 9, death after ablation in 1 old woman with aortic stenosis by collapsus).
Only 8 pts without HD, mean age 52±22, died from CV death (0.7%)
(p<0.000001) (sudden death 2, heart failure 2, SVT ablation-related death 2,
rhythmic surgery-related death 1). Three pts with SVT and HD are in stage IV
of heart failure; 13 pts with HD are in permanent atrial fibrillation (AF)
(10%); only 52 pts without HD are in AF (4.5%) (p<0.01); 3 of them died
from CV death.
Conclusions: We confirm the low risk of SVT-related death in pts without
HD. At contrary, pts with HD and SVT are at high risk of cardiovascular
events despite ablation of SVT. Sudden deaths and heart failure-related deaths
are frequent. They are also at risk of AF.
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Accessory pathway (AP) ablations have exploded in recent years and nat-
ural follow-up of preexcitation syndrome (PS) became difficult. The purpose
of the study was to report the natural changes of clinical and electrophysiolog-
ical data in patients with a PS.
Methods: Electrophysiological study (EPS) was performed in 74 patients,
mean age 31±16 with a PS and was repeated 1 to 21 years later (mean
9 years±6). EPS 1 was indicated for syncope (n=8), atrioventricular reentrant
tachycardia (AVRT) (n=39), atrial fibrillation (AF) (n=3), spontaneous
adverse presentation (n=4) or for asymptomatic PS (n=20). The protocol was
similar at both EPS.
Results: At study 2, clinical data remained unchanged in 39 patients (53%);
12 initially asymptomatic patients became symptomatic (60%); 11 initially symp-
tomatic patients became asymptomatic (20%). At EPS 2 the highest rate con-
ducted by AP was lower in control state and after isoproterenol. AP has lost
anterograde conduction in 22 patients, but 10 had still AVRT. Among 28 patients
with initially rapid conduction through AP, 5 became asymptomatic with a benign
form; 23 have still a rapid conduction at EPS 2; 3 initially asymptomatic patients
developed rapid AF. The frequency of AVRT induction was similar at EPS 1 and
2. The frequency of AF induction tended to decrease (NS).
Conclusions: A benign preexcitation syndrome without inducible AVRT
or AF remains benign. Rate conducted through AP decreases during the life,
but AVRT remains inducible. Patients with AVRT and AP with a long refrac-
tory period become asymptomatic in 15% of cases. There is a discrepancy
between clinical presentation and data of EPS.
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Accessory pathway (AP) ablation is now a current treatment of symptom-
atic patients (pts) with a Wolff-Parkinson-White (WPW) syndrome or pts with
a potentially malignant form at electrophysiological study. The success is con-
sidered as high. The purpose of the study was to look for the prevalence of the
reappearance of symptoms or preexcitation syndrome after ablation.
Methods: Successful AP ablation was performed in 327 pts aged from 10
to 77 years, mean age 35±16, with a WPW. Reappearance of symptoms or of
a preexcitation syndrome on ECG occurred in 50 patients (15%) from several
hours to several years (group I). Clinical and electrophysiological data were
studied in group I and remaining pts (group II).
Results: Group I was younger than group II (31±16 years vs 36±17,
<0.05). There were no differences concerning the gender (male 56% vs 60%)
and the reason of ablation (spontaneous malignant form 20% vs 27%; sponta-
neous AV reentrant tachycardia (AVRT) 60% vs 58%, asymptomatic with
electrophysiological signs of malignancy 20% vs 15%). There is a tendency
(0.08) for a more frequent septal AP location in group I (54%) than in
group II (41%). Other locations did not differ. During follow up, among ini-
tially asymptomatic group I pts, 2 became symptomatic and had inducible
AVRT at the control. Group I pts with spontaneous AVRT presented recur-
rences of AVRT, but 1. Among group I pts with spontaneously malignant
form, 3 pts lost the signs of malignancy at 2nd EPS; one pt who presented only
with rapid AF had an AP with long refractory period but developed incessant
AVRT’s; 6 pts had still signs of malignancy.
Conclusions: The reappearance of symptoms or a preexcitation syndrome on
ECG after AP ablation is not rare (15%) and is generally associated with the
reappearance of all initial electrophysiological properties of AP. Pts without
AVRT before ablation may become symptomatic and develop AVRT after abla-
tion. A young age and a septal AP location were factors of recurrence.
